Candriam Luxembourg S.C.A. lowered its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 30.2% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 220,000 shares of the biopharmaceutical company’s stock after selling 95,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in TG Therapeutics were worth $2,211,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. State Street Corp boosted its stake in TG Therapeutics by 6.7% in the fourth quarter. State Street Corp now owns 679,115 shares of the biopharmaceutical company’s stock valued at $3,157,000 after buying an additional 42,760 shares in the last quarter. Guggenheim Capital LLC boosted its stake in TG Therapeutics by 67.6% in the fourth quarter. Guggenheim Capital LLC now owns 267,985 shares of the biopharmaceutical company’s stock valued at $1,246,000 after buying an additional 108,106 shares in the last quarter. Teachers Advisors LLC boosted its stake in TG Therapeutics by 24.6% in the fourth quarter. Teachers Advisors LLC now owns 70,432 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 13,887 shares in the last quarter. Creative Planning boosted its stake in TG Therapeutics by 3.2% in the first quarter. Creative Planning now owns 32,001 shares of the biopharmaceutical company’s stock valued at $373,000 after buying an additional 1,000 shares in the last quarter. Finally, Bank of Montreal Can bought a new stake in TG Therapeutics during the first quarter valued at approximately $443,000. Institutional investors and hedge funds own 45.68% of the company’s stock.

TG Therapeutics, Inc. (TGTX) opened at 10.10 on Friday. TG Therapeutics, Inc. has a 12 month low of $4.10 and a 12 month high of $15.35. The company’s market cap is $622.73 million. The company’s 50-day moving average is $10.95 and its 200 day moving average is $9.95.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. TG Therapeutics had a negative return on equity of 162.02% and a negative net margin of 68,806.59%. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. Equities analysts forecast that TG Therapeutics, Inc. will post ($1.76) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Candriam Luxembourg S.C.A. Decreases Stake in TG Therapeutics, Inc. (TGTX)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-decreases-stake-in-tg-therapeutics-inc-tgtx/1472848.html.

Several analysts recently commented on TGTX shares. Raymond James Financial, Inc. restated a “buy” rating on shares of TG Therapeutics in a report on Friday, April 21st. Jefferies Group LLC started coverage on shares of TG Therapeutics in a report on Tuesday, April 25th. They set a “buy” rating and a $23.00 price target for the company. FBR & Co restated a “buy” rating on shares of TG Therapeutics in a report on Monday, May 1st. Zacks Investment Research cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. Finally, ValuEngine upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $23.67.

In other TG Therapeutics news, CFO Sean A. Power sold 59,976 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $11.09, for a total transaction of $665,133.84. Following the completion of the transaction, the chief financial officer now owns 477,464 shares of the company’s stock, valued at approximately $5,295,075.76. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 16.70% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.